Korean biosimilar company Celltrion (Kosdaq: 068270) is showing that it can also achieve success with a novel biologic.
The company announced that, through continued partnership with key pharmacy benefit managers (PBMs) and health plans, it has expanded access to Zymfentra (infliximab-dyyb), the first and only US Food and Drug Administration (FDA)-approved subcutaneous (SC) infliximab.
Through these partnerships, Celltrion has now secured comprehensive access across the US health care system.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze